rel-Licogliflozin|CAS 2730989-98-5|DC Chemicals

Cas No.:	2730989-98-5
Chemical Name:	rel-Licogliflozin
SMILES:	O[C@H]1[C@H](C2=CC(CC3=CC=C4C(OCCO4)=C3)=C(CC)C=C2)O[C@H](CO)[C@@H](O)[C@@H]1O
Formula:	C₂₃H₂₈O₇
M.Wt:	416.46
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC39092	Ipragliflozin (L-Proline)	Ipragliflozin L-Proline is an orally active and selective inhibitor of SGLT2 with IC50 of 7.38 nM, 6.73 nM and 5.64 nM for human SGLT2, rat SGLT2 and mouse SGLT2, respectively.
DC10765	LX-2761	LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.
DC76802	rel-Licogliflozin	rel-Licogliflozin is a relative configuration of Licogliflozin.
DC76801	Olorigliflozin	Olorigliflozin is a sodium glucose co-transporter inhibitor with anti-hyperglycemic effects.
DC72660	Henagliflozin	Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research.
DC72659	Sergliflozin etabonate	Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.
DC72658	Velagliflozin (proline)	Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
DC72657	Velagliflozin proline hydrate	Velagliflozin proline hydrate is the clinical form of Velagliflozin. Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.
DC48201	SGLT1/2-IN-2	SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2).